Connor Clark & Lunn Investment Management Ltd. Invests $2.04 Million in DaVita Inc. (NYSE:DVA)

Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of DaVita Inc. (NYSE:DVA) during the 3rd quarter, Holdings Channel reports. The firm bought 12,459 shares of the company’s stock, valued at approximately $2,042,000.

A number of other institutional investors also recently added to or reduced their stakes in DVA. Advisors Asset Management Inc. raised its stake in shares of DaVita by 28.9% during the first quarter. Advisors Asset Management Inc. now owns 9,398 shares of the company’s stock valued at $1,297,000 after purchasing an additional 2,108 shares in the last quarter. BOKF NA increased its stake in DaVita by 286,550.0% during the 1st quarter. BOKF NA now owns 5,733 shares of the company’s stock valued at $790,000 after buying an additional 5,731 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of DaVita by 0.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 85,286 shares of the company’s stock worth $11,775,000 after buying an additional 533 shares in the last quarter. Caxton Associates LP acquired a new stake in shares of DaVita in the 1st quarter worth approximately $233,000. Finally, B. Riley Wealth Advisors Inc. boosted its holdings in shares of DaVita by 9.9% in the first quarter. B. Riley Wealth Advisors Inc. now owns 2,308 shares of the company’s stock valued at $319,000 after acquiring an additional 207 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insider Buying and Selling at DaVita

In other news, CEO Javier Rodriguez sold 9,881 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $162.85, for a total value of $1,609,120.85. Following the transaction, the chief executive officer now owns 887,835 shares in the company, valued at $144,583,929.75. This represents a 1.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 2.00% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. UBS Group upped their target price on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Bank of America raised their target price on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. Barclays lifted their target price on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Finally, Truist Financial upped their price target on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a report on Monday, October 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $161.80.

DaVita Trading Up 0.9 %

Shares of NYSE DVA opened at $166.99 on Tuesday. The business has a fifty day simple moving average of $158.34 and a 200-day simple moving average of $148.65. The company has a market cap of $13.69 billion, a price-to-earnings ratio of 18.01, a P/E/G ratio of 0.93 and a beta of 0.89. DaVita Inc. has a 12 month low of $98.26 and a 12 month high of $169.12. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). The firm had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business’s revenue was up 4.6% on a year-over-year basis. During the same period last year, the business earned $2.85 earnings per share. Sell-side analysts predict that DaVita Inc. will post 9.71 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.